

February 7, 2023

ID and Stewardship in Pediatrics: Considerations for Adult Clinicians

Antimicrobial prescribing is common in non-pediatric settings

Antibiotic use common in non-pediatric settings

- Non-pediatric EDs care for >85% of pediatric ED patients (>25 million visits annually)
→ antibiotics are more commonly prescribed in non-pediatric EDs than pediatric

Inappropriate prescribing in pediatrics is common

- ED → 32% = 2.1 million per year were generally not indicated
- Ambulatory practices → antibiotic prescribing compliance with guidelines for otitis media, pharyngitis, and sinusitis = 21%


Use is associated with harm

- 70,000 children are harmed annually due to antibiotics necessitating an ED visit




Respiratory infections are main driver of visits


Most frequent visits by ID subgroup



Hospitalizations by ID subgroup




Developmental changes in pediatrics



PK Implications

- Weakly acidic drugs: ↓ bioavailability
 - Example drugs: ganciclovir
- Weakly basic drugs: ↑ bioavailability
 - Example drugs: penicillin, ampicillin, nafcillin

Developmental changes in pediatrics



PK Implications

- Hydrophilic drugs: ↑ volume of distribution = drug dosing in neonates requires higher mg/kg amount compared to adults
 - Example drugs: gentamicin, vancomycin
- Lipophilic drugs: ↓ volume of distribution
- Lower protein concentrations and affinity in <1 year = lower binding to highly protein bound agents



Developmental changes in pediatrics

Premature infant
<37 wk gestation



Neonate
<28 days



Infant
<1 year



Toddler
2-3 years




Child/Adolescent
2-16 years



Metabolism

Low CYP450 content (30-60% of adult)

Normal CYP450 content



PK Implications

- Lower enzyme activity: ↓ hepatic clearance

Lu, et al. *Developmental Pharmacokinetics*. 2019.
Batchelor et al. *British Journal of Pharmacology*. 2013.
Yellepeddi et al. *Advanced Drug Delivery Reviews*. 2019.

Developmental changes in pediatrics

Premature infant
<37 wk gestation



Neonate
<28 days



Infant
<1 year



Toddler
2-3 years



Child/Adolescent
2-16 years



Renal Elimination


Lower glomerular filtration
rate (GFR): 5-10 mL/min/m²

Normal GFR
Normal renal tubular secretion

Low GFR: 10-15 mL/min/m²
Lower renal tubular secretion

PK Implications

- Lower GFR: ↓ renal clearance
- Lower renal tubular secretion: ↓ renal clearance
- Example drugs: aminoglycosides, penicillins, cephalosporins



Developmental changes in pediatrics

Key takeaways

- In neonates and young infants (<2 months), age-specific dosing regimens are needed
- In infants ≥ 2 months, use weight-based dosing and adjust in those with impaired renal function
- Pediatric dosing handbooks are a must

Antibiotics			
Amikacin IV	Cefoxitin IV	Ciprofloxacin IV	Metronidazole IV
Amoxicillin PO	Cefpodoxime PO	Clindamycin IV/PO	Nafcillin IV
Amoxicillin-clavulanate PO	Ceftaroline IV	Daptomycin IV	Nitrofurantoin PO
Ampicillin IV	Ceftazidime IV	Doxycycline IV/PO	Penicillin G IV
Ampicillin-sulbactam IV	Ceftazidime-avibactam IV	Ertapenem IV	Piperacillin-tazobactam IV
Azithromycin IV/PO	Ceftriaxone IV	Gentamicin IV	Rifampin IV/PO
Aztreonam IV	Cefuroxime Axetil PO	Imipenem IV	TMP-SMX IV/PO
Cefazolin IV	Cefuroxime IV	Levofloxacin IV/PO	Tobramycin IV
Cefepime IV	Cephalexin PO	Linezolid IV/PO	Vancomycin IV
Cefixime PO	Ciprofloxacin PO	Meropenem IV	
Antifungals			
Amphotericin B, liposomal IV	Itraconazole PO	Pentamidine IV	Voriconazole IV/PO
Fluconazole IV/PO	Micafungin IV	Posaconazole IV/PO	
Antivirals			
Acyclovir IV	Foscarnet IV	Oseltamivir PO	Valgancyclovir PO
Cidofovir IV	Ganciclovir IV	Peramivir IV	Zanamivir INH
Notes			
Footnotes		References	



Doxycycline use in pediatrics: time to change?

- Tooth discoloration appreciated in early 1960s with tetracycline
- Doxycycline exhibits less calcium binding (19%) compared to tetracycline (39.5%-75.4%)
- Re-evaluation of doxycycline in children found no evidence of doxycycline associated tooth discoloration

Red Book updated recommendation in 2018: "These reassuring data support the recommendation by AAP that doxycycline can be administered for short duration (ie, 21 days or less) without regards to the patient's age."



Stewardship Considerations

- Tailor stewardship efforts by age and diagnosis
 - Delayed antibiotic prescriptions for certain diagnosis, such as acute otitis media
- Clinicians are protocol driven with conditions less likely encountered
- Family partnerships are key
 - Communication coupled with contingency plans can improve care and satisfaction



Utilize resources from pediatric settings

Guidelines for common infections



<https://idmp.ucsf.edu/guidelines-for-empiric-therapy-pediatrics>



<https://www.stanfordchildrens.org/content-public/pdf/antimicrobial-stewardship-program/guidelines-for-initial-therapy-for-common-pediatric-infections.pdf>



<https://www.seattlechildrens.org/health-care-professionals/gateway/clinical-resources/pathways/>



<https://www.med.umich.edu/asp/peds.html>



<https://www.childrensmercy.org/siteassets/media-documents-for-depts-section/documents-for-health-care-providers/evidence-based-practice/clinical-practice-guidelines--care-process-models/outpatient-antibiotic-handbook.pdf>



"Stewie Shares" Infographics



2022

- **A Not Too DIFFicult C. Diff Review**
- **Strep Throat: A Common Conundrum**
- **Penicillin Allergies: What's True and What to Do?**

2021

- **Prescribing an Antibiotic? Tidbits to Teach Families**
- **A Consumer's Guide to Fluoroquinolones**
- **Dispose Antibiotics Safely. Prevent Resistance.**
- **Five Facts about Community Acquired Pneumonia**
- **Five Helpful Tips to Make Giving Antibiotics Easier for You**
- **Flu Who? Reviewing the Prevention and Treatment of Influenza**
- **Four Vaccines You Didn't Know You Needed**
- **IV is not Always the Answer**
- **Preventing RSV... As Easy as 1,2,3**
- **"Tick" Talk**

5 Facts
COMMUNITY ACQUIRED PNEUMONIA

Stewie's Shares
Monthly Antimicrobial Memo
December 2020

COMMUNITY ACQUIRED PNEUMONIA CLINICAL PRACTICE GUIDELINES

Did you know that CM recently updated the Community Acquired Pneumonia (CAP) Clinical Practice Guideline (CPG)? A recent change is the recommendation to use ampicillin/sulbactam instead of clindamycin + ceftriaxone to treat complicated CAP due to low rates of MRSA identified in patients with CAP at CM (2% of pleural fluid cultures) The CPG can be found [here](#).

ANTIBIOTIC OF CHOICE

Studies in both the [inpatient](#) and [outpatient](#) settings report variability in antibiotic prescribing and deviation from guidelines to treat CAP. Use of broad-spectrum antibiotics, such as ceftriaxone, [do not improve outcomes](#) in uncomplicated CAP. High-dose ampicillin or amoxicillin should be used first-line & provide excellent coverage against Streptococcus pneumoniae, the most likely bacteria.

AZITHROMYCIN USE IN COMMUNITY ACQUIRED PNEUMONIA

Even though a Z-Pak (azithromycin) may be easy to prescribe, azithromycin is not always the best option for adult or pediatric CAP. There is increasing resistance, and only 57% of Streptococcus pneumoniae isolates at CM are adequately treated by azithromycin. Azithromycin can be considered for treatment of CAP caused by atypical pathogens (i.e., Mycoplasma), although [benefit is controversial](#).

AUGMENTIN (AMOXICILLIN/CLAVULANATE) FORMULATION

Specific formulations of amoxicillin/clavulanate, including extra-strength oral suspension (600 mg amoxicillin/5 mL) or XR capsules, should only be selected when prescribing high dose amoxicillin/clavulanate for CAP. Other formulations provide too much clavulanate which leads to abdominal pain, nausea, & diarrhea. A dosage formulation selection table may be found in [here](#).

DURATION OF TREATMENT

Existing guidelines have recommended 10 days of antibiotics to treat CAP, however more recent data support shorter treatment courses in both children and adult patients. A [recent pediatric study](#) compared short (5-7 days) vs. long (8-14 day) antibiotic treatment courses. No differences were observed in treatment failure between groups, which supports a 5-7 day course of antibiotics for treatment for uncomplicated CAP.

CMH Antimicrobial Stewardship Program
AntimicrobialStewards@cmh.edu



Differences in treatments by age

Diagnosis	Adult patients		Pediatric patients	
	Organization (publication year)	First-line therapy	Organization (publication year)	Pediatric population included
Community acquired pneumonia	IDSA (2019) ²⁸	No comorbidities: (1) Amoxicillin (2) doxycycline (3) azithromycin Comorbidities: (1) Amoxicillin-clavulanate + macrolide OR doxycycline (2) Cefpodoxime OR cefuroxime + macrolide OR doxycycline (3) Levofloxacin OR moxifloxacin	IDSA (2011) ²⁹	Infants and Children <div>Antimicrobial therapy not routinely recommended for preschool-aged children</div> All ages: Amoxicillin
Acute bacterial rhinosinusitis	IDSA (2012) ⁸	Children: Amoxicillin-clavulanate Adults: Amoxicillin-clavulanate	AAP (2013) ⁹	1-18 years Uncomplicated, mild to moderate, and ≥ 2 years: Amoxicillin Risk of resistance, moderate to severe, OR ≤ 2 years: Amoxicillin-clavulanate
Uncomplicated cystitis and pyelonephritis in women	IDSA (2011) ³⁰	Cystitis: (1) Nitrofurantoin (2) Trimethoprim-sulfamethoxazole (3) Fosfomycin Pyelonephritis: (1) Ciprofloxacin (2) Levofloxacin (3) Trimethoprim-sulfamethoxazole Beta-lactams are NOT routinely recommended	AAP (2016) ³¹	2 – 24 months Empiric Oral Antibiotics: (1) Cephalexin (2) Cefixime (3) Cefpodoxime (4) Cefprozil (5) Amoxicillin-clavulanate (6) Trimethoprim-sulfamethoxazole

AAP, American Academy of Pediatrics; IDSA, Infectious Diseases Society of America.



Summarized Considerations for Adult Clinicians

- 1) Differences in physical size, body composition, and organ system maturation
- 2) Tailor stewardship efforts by age and diagnosis
- 3) Develop strong family partnerships
- 4) Utilize resources from pediatric institutions
- 5) Differences in infectious presentations, diagnoses, and treatments by age

